These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23979963)

  • 1. The road not taken: transferability issues in multinational trials.
    Vemer P; Rutten-van Mölken MP
    Pharmacoeconomics; 2013 Oct; 31(10):863-76. PubMed ID: 23979963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.
    Manca A; Lambert PC; Sculpher M; Rice N
    Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
    Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
    Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian modelling of healthcare resource use in multinational randomized clinical trials.
    Gauthier A; Manca A; Anton S
    Pharmacoeconomics; 2009; 27(12):1017-29. PubMed ID: 19908926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.
    Torti FM; Reed SD; Schulman KA
    Value Health; 2006; 9(5):281-91. PubMed ID: 16961546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
    Richardson G; Manca A
    Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate.
    Willan AR; Kowgier ME
    Health Econ; 2008 Jul; 17(7):777-91. PubMed ID: 17764096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.
    Augustovski F; Iglesias C; Manca A; Drummond M; Rubinstein A; Martí SG
    Pharmacoeconomics; 2009; 27(11):919-29. PubMed ID: 19888792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries.
    Boehler CE; Lord J
    Med Decis Making; 2016 Jan; 36(1):31-47. PubMed ID: 25878194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.
    Velentzis LS; Salagame U; Canfell K
    BMC Health Serv Res; 2017 May; 17(1):326. PubMed ID: 28476121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].
    Amato L; Colais P; Davoli M; Ferroni E; Fusco D; Minozzi S; Moirano F; Sciattella P; Vecchi S; Ventura M; Perucci CA
    Epidemiol Prev; 2013; 37(2-3 Suppl 2):1-100. PubMed ID: 23851286
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.